Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

被引：0
|
作者：
Ketil A. Camilio
Meng-Yu Wang
Brynjar Mauseth
Stein Waagene
Gunnar Kvalheim
Øystein Rekdal
Baldur Sveinbjørnsson
Gunhild M. Mælandsmo
机构：
[1] Institute for Cancer Research,Department of Tumor Biology
[2] Oslo University Hospital,Department of Cellular Therapy
[3] Oslo University Hospital,Department of Medical Biology
[4] Lytix Biopharma AS,Division of Cancer, Surgery and Transplantation
[5] The Arctic University of Norway,Institute of Clinical Medicine
[6] Oslo University Hospital,undefined
[7] University of Oslo,undefined
[8] Oslo Cancer Cluster Incubator,undefined
来源：
Breast Cancer Research | / 21卷
关键词：
Triple-negative breast cancer; Immunochemotherapy; Combination therapy; Immunotherapy; Oncolytic peptide; LTX-315; Doxorubicin; DAMPs; ICD;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
    Munkacsy, Gyongyi
    Santarpia, Libero
    Gyorffy, Balazs
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
  • [22] Peroxiporins in Triple-Negative Breast Cancer: Biomarker Potential and Therapeutic Perspectives
    Bijelic, Anita
    Silovski, Tajana
    Mlinaric, Monika
    Gasparovic, Ana Cipak
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
  • [23] Therapeutic Strategies in Triple-Negative Breast Cancer
    Paradiso, Angelo
    Singer, Christian F.
    BREAST CARE, 2017, 12 (01) : 6 - 7
  • [24] Therapeutic Strategies for Triple-Negative Breast Cancer
    Tan, Antoinette R.
    Swain, Sandra M.
    CANCER JOURNAL, 2008, 14 (06): : 343 - 351
  • [25] Triple-negative breast cancer: therapeutic options
    Cleator, Susan
    Heller, Wolfgang
    Coombes, R. Charles
    LANCET ONCOLOGY, 2007, 8 (03): : 235 - 244
  • [26] Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer
    Saghaeidehkordi, Azam
    Chen, Shiuan
    Yang, Sun
    Kaur, Kamaljit
    PHARMACEUTICS, 2021, 13 (05)
  • [27] CXCL16 as a potential therapeutic target of triple-negative breast cancer
    Cho, Sun Wook
    Jang, Mi Gyeong
    Sun, Hyun Jin
    Lee, Han Sai
    Song, Young Shin
    Kim, Seong Keun
    CANCER RESEARCH, 2022, 82 (04)
  • [28] LRP5: a Potential Therapeutic Target in Triple-negative Breast Cancer
    Maubant, S.
    Maire, V.
    Tesson, B.
    Gentien, D.
    Marty-Prouvose, B.
    Cruzalegui, F.
    Depil, S.
    Tucker, G. C.
    Roman-Roman, S.
    Dubois, T.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 161 - 162
  • [29] PARP1 in triple-negative breast cancer: Expression and therapeutic potential
    Cotter, M. B.
    Pierce, A.
    McGowan, P. M.
    Madden, S. F.
    Flanagan, L.
    Quinn, C.
    Evoy, D.
    Crown, J.
    McDermott, E.
    Duffy, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] LRP5: a potential therapeutic target in triple-negative breast cancer
    Maubant, Sylvie
    Maire, Virginie
    Tesson, Bruno
    Gentien, David
    Marty-Prouvost, Berengere
    Cruzalegui, Francisco
    Depil, Stephane
    Tucker, Gordon C.
    Roman-Roman, Sergio
    Dubois, Thierry
    CANCER RESEARCH, 2013, 73 (08)
12345